Hormone therapy for breast cancer Cancer
Conditions
Interventions
WP 1: Intervention development
1a. A rapid scoping review of the literature to identify the best available evidence on patient medication diary interventions for cancer patients.
1b. Two co-design Wor
ii. WS2: Develop content for a medication consultation guide for pharmacists and training content.
1c. Qualitative interviews with pharmacists: We will explore the views of pharmacist representatives
Sponsors
London Metropolitan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: WP1 - 1c. Qualitative interviews with pharmacists: 1. Pharmacists who are owner or manager of a community pharmacy, chain and independent; 2. pharmacists with a representative role in professional pharmaceutical bodies, e.g. Local Pharmaceutical Committee, Community Pharmacy England, Royal Pharmaceutical Society. WP2 - 2b. Qualitative interviews with pharmacists: 1. A pharmacist or pharmacist technician, permanent or locum (and) 2. Working in community pharmacies located in London (and) 3. Providing hormone therapy medication to clients WP3 – Testing and optimisation studies Pharmacists: 1. Pharmacists and pharmacy technicians; from the London boroughs of Barnet, Camden, Enfield, Haringey, or Islington 2. Providing Hormone Therapy medication to clients 3. Agree to participate in online training 4. Agree to recruit 4 patients from their pharmacy 5. Agree to deliver a medication consultation with recruited participants and audio record 1 consultation (with patient consent), and provide feedback notes of the consultation. 6. Agree to provide feedback in a study follow-up interview. 7. Is willing to provide written (signed and dated) informed consent. Patients: 1. Women 18+ years with early BC (stage 1-3); 2. Talking oral HT medication (tamoxifen, anastrozole, or letrozole) and had/have concerns about changing HT brands; 3. Not taking HT medication as neo-adjuvant or secondary metastatic BC; 4. Is willing and able to record notes on side effects and medication taken (diary) and attend a medication consultation with the CP; 5. Is willing and able to participate in a study follow-up interview (phone or video conference); 6. Is willing to provide a copy of the diary; 7. Is willing to be audio recorded during the pharmacy consultation; 8. Is willing to provide written (signed and dated) informed consent.
Exclusion criteria
Exclusion criteria: WP1 - 1c. Qualitative interviews with pharmacists: 1. locum, technician, assistants, pharmacist not owner or manager 2. Pharmacists without a representative role in professional pharmaceutical bodies WP2 - 2b. Qualitative interviews with pharmacists: 1. Accredited Checking Technician, assistants WP3 – Testing and optimisation studies Pharmacists: 1. Locum, Accredited Checking Technician, pharmacy assistants. Patients: 1. Male 2. Currently or recently (last 6 months) involved in another research study where medication adherence is a primary outcome; 3. Have had in the last 6 months a medication review about changing brands of HT drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Qualitative interviews to optimise the usability, practicality and acceptability of the intervention for community pharmacists and breast cancer patients. Using behavioural analysis constructs from the Theoretical Domains Framework and the Person-Based Approach for intervention development conducted 2 or 3 weeks after the testing of the intervention in WP3 | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Outcome results
None listed